­
4:44 pm 4:44 pm

Pneumonia Vaccine Shown to Actually Increase Bacterial Infections It Is Supposed to Prevent

December 28th, 2014|Authorities Speak Out, blog, Pneumococcal, Pneumococcal Vaccine Ineffectiveness, Pneumococcal Vaccine Risk, Vaccine Ineffectiveness, Vaccine Risks|

It’s estimated that nearly one in 7 U.S. adults have been diagnosed with sinusitis in the past 12 months, which occurs when the mucous membranes in your nose and sinuses become irritated. In most of these cases (90-98%) a virus is the cause, whereas in 2-10% of cases, a bacterial infection is also present.These bacterial infections are becoming increasingly drug-resistant and therefore harder and harder to treat, which is why the Infectious Diseases Society of America (IDSA) recently issued new treatment guidelines for sinusitis.

Alarmingly, however, buried on page 16 of their report is the acknowledgement that certain hard-to-treat bacterial infections in children are on the rise because of the widespread use of the conjugated pneumococcal vaccines!

Bacterial Infections on the Rise Since Introduction of the Pneumonia Vaccine

The IDSA report states:
” … both the prevalence of H. influenzae (40%– 45%) and proportion of b-lactamase–producing H. influenzae (37%–50%) (extrapolated from middle ear fluid cultures of children with acute otitis media) have markedly increased among other upper respiratory tract infections since the widespread use of conjugated pneumococcal vaccines… Whereas S. pneumoniae was more common than H. influenzae prior to 2000, the prevalence of H. influenzae has clearly increased while that of S. pneumoniae has decreased in the post–pneumococcal vaccine era, such that currently they are approximately equal … “

In the United States the Prevnar vaccine, which is used to prevent pneumoccocal disease that can cause meningitis and bloodstream infections in young children, was licensed in 2000 and has been given to infants in four

8:28 pm 8:28 pm

Pneumovax II

February 25th, 2014|Pneumococcal, Vaccine Brands|

Pneumovax II Pneumococcal Vaccine, Polyvalent
Manufacturer Sanofi Pasteur MSD
Microorganism Most common types for S. pneumoniae bacteria
Licensed 01/2006
Recommendations Single 0.5 mL i.m. or s.c. injection for adults and children 2 years of age or older.
Ingredients Phenol, Sodium chloride
Product Descriptions
8:25 pm 8:25 pm

Pneumovax® 23

February 25th, 2014|Pneumococcal, Vaccine Brands|

Pneumovax® 23 Pneumococcal 23-valent polysaccharide vaccine (PS), inactivated
Manufacturer Merck
Microorganism S. pneumoniae, serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F
Licensed 11/21/1977
Recommendations One i.m. or s.c. injection and a booster is recommended.
Ingredients Phenol, Pneumococcal Polysaccharide(s), Isotonic saline
Product Descriptions Package insert
8:19 pm 8:19 pm

Pnu-Imune® 23

February 25th, 2014|Pneumococcal, Vaccine Brands|

Pnu-Imune® 23 (PS) 23-valent polysaccharide vaccine
Manufacturer Wyeth
Microorganism S. pneumoniae bacteria
Licensed 08/15/1979
Recommendations Single i.m. or s.c. injection for those 2 years of age and older.
Ingredients Thimerosal, 2-(ethylmercurithio) benzoic acid, Pneumococcal Polysaccharide(s)
Product Descriptions
8:16 pm 8:16 pm

Prevnar®

February 25th, 2014|Pneumococcal, Vaccine Brands|

Prevnar® Pneumococcal Conjugate Vaccine 7-valent, inactivated
Manufacturer Wyeth
Microorganism S. pneumonia bacteria, serotypes 4, 9V, 14, 18C, 19F, and 23F
Licensed 11/22/2006
Recommendations 4 i.m. injections at 2, 4, 6, and 12 to 15 months of age.
Ingredients Latex, Aluminum phosphate, Soy protein
Product Descriptions